TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1393035

Group type: EXPERIMENTAL
Intervention: salcatonin 200 IU
Number of subjects: 208

Group type: COMPARATOR
Intervention: calcium (placebo)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: salcatonin
Number of subjects: 208
Study: 3930143

Group type: EXPERIMENTAL
Intervention: Four levonorgestrel covered rods
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Six levonorgestrel covered rods
Number of subjects: 146

Group type: COMPARATOR
Intervention: Non-hormonal contraceptors (Control)
Number of subjects: 146
Study: 31902455

Group type: EXPERIMENTAL
Intervention: Remote-access CT scanner (RA) with peer-assisted learning (PAL)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Local-access CT scanner (LA) facilitated by a CT radiographer
Number of subjects: 62
Study: 30395266

Group type: EXPERIMENTAL
Intervention: IUI with ovarian stimulation (IUI-OS)
Number of subjects: 1896

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1896
Study: 28226308

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) for weight loss
Number of subjects: 74

Group type: COMPARATOR
Intervention: Attentional control
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Participants with BED
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Participants without BED
Number of subjects: 74
Study: 25733516

Group type: EXPERIMENTAL
Intervention: Purified recombinant LppQ‐N' formulated in Freund's adjuvant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24899755

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.5 mg/day
Number of subjects: 85
Study: 21976367

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg) every 6 months for 3 years
Number of subjects: 7808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7808
Study: 20176737

Group type: EXPERIMENTAL
Intervention: 1 mg GH/m(2) per day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 2 mg GH/m(2) per day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 41
Study: 17954798

Group type: EXPERIMENTAL
Intervention: Standard-dose reteplase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose abciximab plus half-dose reteplase
Number of subjects: 0
Study: 16279158

Group type: COMPARATOR
Intervention: Home oxygen therapy (HOT)
Number of subjects: 170
Study: 11990447

Group type: EXPERIMENTAL
Intervention: Bioabsorbable barrier (polyglactin 910; test: T)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-resorbable barrier (expanded polytetrafluoroethylene [ePTFE]; control: C)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 12
Study: 10440620

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400 mg loading dose, followed by 200 mg once daily for 10 days)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Clarithromycin (500 mg twice daily for 10 days)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 298

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 298
Study: 7784810

Group type: EXPERIMENTAL
Intervention: Procaine penicillin 100,000 IU (PP100)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Procaine penicillin 200,000 IU (PP200)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Procaine penicillin 400,000 IU (PP400)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Tetracycline 250 mg (TTC)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Overall case fatality rate
Number of subjects: 184
Study: 1982108

Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine at bedtime
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 150 mg nizatidine BID
Number of subjects: 101

Group type: COMPARATOR
Intervention: 150 mg ranitidine BID
Number of subjects: 101
Study: 538813

Group type: EXPERIMENTAL
Intervention: Single injection of long-acting chloramphenicol (Tifomycine)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Five-day course of crystalline and procaine penicillin
Number of subjects: 131
Study: 31815705

Group type: EXPERIMENTAL
Intervention: Real rTMS (2000 pulses; 20 Hz; 90% RMT; 10 trains of 10 s with 25 s between each train) for 10 days followed by 5 booster sessions every month for 3 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 33
Study: 31134354

Group type: EXPERIMENTAL
Intervention: HBsAg positive samples
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: anti-HBs positive samples
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: anti-HBc positive samples
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: anti-HDV positive samples
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: anti-HCV positive samples
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: anti-HIV-1 positive samples
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: anti-HTLV I/II positive samples
Number of subjects: 492
Study: 28135143

Group type: COMPARATOR
Intervention: Cisplatin plus Etoposide (arm A)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Cisplatin plus Etoposide with Bevacizumab (arm B)
Number of subjects: 204
Study: 27053392

Group type: EXPERIMENTAL
Intervention: Re-transfusion from the drain (RTF2)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard drainage (DRN2)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Re-transfusion from the drain (RTF)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard drainage (DRN)
Number of subjects: 101
Study: 24077206

Group type: EXPERIMENTAL
Intervention: Milnacipran (200 mg/day)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Milnacipran (any dose)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 21427644

Group type: EXPERIMENTAL
Intervention: Structured intergenerational volunteering intervention (hour-long sessions with kindergarten and older elementary classes for 5 months)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study: 19139382

Group type: EXPERIMENTAL
Intervention: Good health status (KCCQ scores > or =75)
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: Fair health status (KCCQ, 50 to 74)
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: Poor health status (KCCQ, 25 to 49)
Number of subjects: 1516
Study: 17495195

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric band surgical program
Number of subjects: 61

Group type: COMPARATOR
Intervention: Medical program using a very-low-energy diet and orlistat
Number of subjects: 61
Study: 15709844

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive changes in pregain sessions
Number of subjects: 0
Study: 12122526

Group type: EXPERIMENTAL
Intervention: Dopexamine infusion (up to 2 mcg/kg/min for up to 7 days)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (no dopexamine infusion)
Number of subjects: 102
Study: 10220637

Group type: EXPERIMENTAL
Intervention: Syncope alone
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Syncope with ventricular tachycardia
Number of subjects: 486

Group type: COMPARATOR
Intervention: Spontaneous ventricular tachycardia
Number of subjects: 486

Group type: COMPARATOR
Intervention: Ventricular fibrillation
Number of subjects: 486
Study: 7570898

Group type: EXPERIMENTAL
Intervention: Screening and treatment programme for imported intestinal parasites
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 2195860

Group type: EXPERIMENTAL
Intervention: Acebutolol, 200 mg twice daily
Number of subjects: 607

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 607
Study: 428086

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg q.a.m.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (normal PRA EHT subgroup)
Number of subjects: 84
Study: 31604115

Group type: EXPERIMENTAL
Intervention: Inhibition of CCL2
Number of subjects: 0

Group type: COMPARATOR
Intervention: High CCL2 expression
Number of subjects: 0
Study: 30238517

Group type: EXPERIMENTAL
Intervention: Cemented lithium disilicate crown on a customized zirconia abutment (CEM)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Screw‐retained crown with a directly veneered zirconia abutment (SCREW)
Number of subjects: 33
Study: 27733398

Group type: EXPERIMENTAL
Intervention: High-frequency physical activity (HF): 50 min/d, 6 d/wk (300 min/wk)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Low-frequency physical activity (LF): 100 min/d, 3 d/wk (300 min/wk)
Number of subjects: 75
Study: 24821476

Group type: EXPERIMENTAL
Intervention: White matter hyperintensity volume
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Apolipoprotein E ε4 status
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Entorhinal cortex volume (ECV)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: High ECV and low WMH
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination score decline of 3 or more points over 6 months or 6 or more points over 12 months
Number of subjects: 332
Study: 22543316

Group type: EXPERIMENTAL
Intervention: 6-week conditioning programme comprising two 1-hr sessions of circuit and vibration training per week
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 20524934

Group type: EXPERIMENTAL
Intervention: Atorvastatin and telmisartan (ARB) for 12 months
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Atorvastatin and enalapril (ACEI) for 12 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: CAD group (baseline)
Number of subjects: 66

Group type: COMPARATOR
Intervention: High levels of miR-146a and TLR4 mRNA/TLR4 protein at baseline
Number of subjects: 66
Study: 17506741

Group type: EXPERIMENTAL
Intervention: Upper body forced‐air warming (Bair Hugger, Augustine Medical model 500/OR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electric heating pad (Operatherm 202, KanMed)
Number of subjects: 60
Study: 15669892

Group type: EXPERIMENTAL
Intervention: quetiapine (400 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: risperidone (4 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: fluphenazine (12.5 mg/day)
Number of subjects: 38
Study: 12691536

Group type: EXPERIMENTAL
Intervention: ISIS 2302 (antisense phosphorothioate oligonucleotide) at a fixed dose regimen of 250-400 mg, given three times weekly
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 10496186

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant IFN beta‐1a (Rebif, Ares‐Serono) 22 microg once a week (QW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant IFN beta‐1a (Rebif, Ares‐Serono) 22 microg three times a week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant IFN beta‐1a (Rebif, Ares‐Serono) 66 microg once a week (QW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9150968

Group type: EXPERIMENTAL
Intervention: Cold provocation at 10 degrees C on the fifth finger of one hand.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Systolic pressures measured in air of four fingers of both hands and both arms.
Number of subjects: 12
Study: 2269924

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine and hydrocortisone cream 1% (used in combination)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone cream 1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixture of silver sulfadiazine and hydrocortisone cream
Number of subjects: 0
Study: 6102442

Group type: EXPERIMENTAL
Intervention: Terfenadine 20 mg tid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpheniramine maleate 4 mg tid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terfenadine (up to 200 mg tid)
Number of subjects: 0
Study: 31093925

Group type: EXPERIMENTAL
Intervention: Counselor-initiated behavioral weight loss intervention
Number of subjects: 248
Study: 30926188

Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided insertion
Number of subjects: 1174

Group type: COMPARATOR
Intervention: Landmark insertion
Number of subjects: 1174
Study: 27893267

Group type: EXPERIMENTAL
Intervention: Online expressive writing intervention
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Active duty deployment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Reserves or National Guard deployment
Number of subjects: 100
Study: 25769593

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 70
Study: 23282124

Group type: EXPERIMENTAL
Intervention: Valsartan (80‐320 mg) with bedtime dosing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Valsartan (80‐320 mg) with awakening dosing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patients with dipping BP pattern
Number of subjects: 60
Study: 20638877

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine infusion (100‐h, starting at 5 mg/h to 20 mg/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 60
Study: 19085034

Group type: EXPERIMENTAL
Intervention: Xylitol gum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 16716315

Group type: EXPERIMENTAL
Intervention: Laparoscopic unilateral tubal fulguration (treatment group, 7 patients)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No surgical intervention (control group, 6 patients)
Number of subjects: 13
Study: 15633319

Group type: EXPERIMENTAL
Intervention: EMD + collagen (EMDC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Collagen membrane (GTRC)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both treatments (GTRC and EMDC)
Number of subjects: 26
Study: 11680558

Group type: EXPERIMENTAL
Intervention: 1‐session exposure treatment alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1‐session treatment with a parent present
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait‐list control group
Number of subjects: 60
Study: 9159367

Group type: EXPERIMENTAL
Intervention: Magnetization transfer (MT) imaging in HIV-positive patients with PML
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Magnetization transfer (MT) imaging in HIV-positive patients with HIV encephalitis
Number of subjects: 33

Group type: COMPARATOR
Intervention: Magnetization transfer (MT) imaging in healthy control subjects
Number of subjects: 33
Study: 7971000

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (10 mg/kg/day, once daily for 10 days)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Cefixime (8 mg/kg/day, once daily for 10 days)
Number of subjects: 368
Study: 2446077

Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg orally once or twice daily for 4 weeks)
Number of subjects: 21
Study: 30764805

Group type: EXPERIMENTAL
Intervention: Vitamin D therapy (800 IU cholecalciferol daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 29133894

Group type: EXPERIMENTAL
Intervention: Microalbuminuria (MAU)
Number of subjects: 3385

Group type: EXPERIMENTAL
Intervention: Microalbuminuria (MAU) in non-pre-diabetic population
Number of subjects: 3385
Study: 25209918

Group type: EXPERIMENTAL
Intervention: Hypothetical vignette with designated driver program
Number of subjects: 390

Group type: COMPARATOR
Intervention: Hypothetical vignette without designated driver program
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Transport relying on someone else to drive home
Number of subjects: 390
Study: 23911205

Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS/pAOS mixture
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 113
Study: 21514808

Group type: EXPERIMENTAL
Intervention: Zinc supplementation and influenza vaccine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Influenza vaccine only
Number of subjects: 2
Study: 18543483

Group type: EXPERIMENTAL
Intervention: Bushen Houxue (BSHX) method combined with ultrasound-guided follicle aspiration (MFA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ultrasound-guided follicle aspiration (MFA) alone (Control group)
Number of subjects: 44
Study: 17058105

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15-30 mg/day)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Olanzapine (10-20 mg/day)
Number of subjects: 214
Study: 15623462

Group type: EXPERIMENTAL
Intervention: DIM (108 mg/day) for 30 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 19
Study: 11398550

Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (MAA) worn for 4-6 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Maxillary placebo appliance worn for 4-6 weeks
Number of subjects: 28
Study: 9269786

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: S-form PML-RAR alpha mRNA
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: S-form vs L-form PML-RAR alpha mRNA
Number of subjects: 230
Study: 8489569

Group type: EXPERIMENTAL
Intervention: Diclofenac-sucralfate association (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Enteric-coated tablets (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diclofenac-sucralfate association
Number of subjects: 12
Study: 21263970

Group type: EXPERIMENTAL
Intervention: Phone group (notified by telephone)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Drop-in group (informed during visits)
Number of subjects: 243
Study: 28981379

Group type: EXPERIMENTAL
Intervention: Computer-delivered, single-session brief motivational intervention plus booster session
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Health checkup for expectant moms (HCEM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 27610245

Group type: EXPERIMENTAL
Intervention: Physical activity consultation and pram walking group intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24434886

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 22115976

Group type: EXPERIMENTAL
Intervention: Alloderm graft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mucosal graft
Number of subjects: 20
Study: 20048389

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 95
Study: 18042835

Group type: EXPERIMENTAL
Intervention: Sequential dose-dense epirubicin 110 mg/m(2) and paclitaxel 250 mg/m(2)
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Concurrent epirubicin 83 mg/m(2) and paclitaxel 187 mg/m(2)
Number of subjects: 1121
Study: 15691532

Group type: COMPARATOR
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: CBT plus Fluoxetine (60 mg/day)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: CBT plus Placebo
Number of subjects: 108
Study: 12618901

Group type: EXPERIMENTAL
Intervention: Concurrent weekly paclitaxel with radiotherapy (group 1)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Radiotherapy alone (group 2)
Number of subjects: 51
Study: 11299268

Group type: EXPERIMENTAL
Intervention: Endurance-exercise training program for 20 weeks
Number of subjects: 364
Study: 9815842

Group type: EXPERIMENTAL
Intervention: rIFN‐alpha (3 x 10(6) units/m2 for 14 days)
Number of subjects: 15
Study: 7948356

Group type: EXPERIMENTAL
Intervention: Nasogastric intubation
Number of subjects: 74

Group type: COMPARATOR
Intervention: No nasogastric intubation
Number of subjects: 74
Study: 3285943

Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 137

Group type: COMPARATOR
Intervention: iopromide
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: iopamidol and iopromide
Number of subjects: 137
Study: 31615934

Group type: EXPERIMENTAL
Intervention: EUS examination after 3-5 mL submucosal saline injection (SSI)
Number of subjects: 180

Group type: COMPARATOR
Intervention: EUS only examination
Number of subjects: 180
Study: 30031572

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg daily
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 26755408

Group type: EXPERIMENTAL
Intervention: Incremental submaximal cycling exercise
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (healthy, inactive)
Number of subjects: 27
Study: 24256157

Group type: EXPERIMENTAL
Intervention: Supervised consumption of methadone or buprenorphine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Unsupervised consumption of methadone or buprenorphine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Supervised consumption
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Flexibly timed discontinuation of supervision
Number of subjects: 29
Study: 23582628

Group type: EXPERIMENTAL
Intervention: Zofenopril 15 to 30 mg/day
Number of subjects: 224

Group type: COMPARATOR
Intervention: Ramipril 5 to 10 mg/day
Number of subjects: 224
Study: 20605858

Group type: EXPERIMENTAL
Intervention: Graded aerobic exercise training (20-40 minutes of stationary cycling and treadmill exercise, 5 days/week for 4 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (16 exercises performed with single set, moderate load and high repetitions, 5 days/week for 4 weeks)
Number of subjects: 22
Study: 18984840

Group type: EXPERIMENTAL
Intervention: Riboflavin (200 mg daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 16616233

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg daily for 12 weeks)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 13
Study: 12783911

Group type: EXPERIMENTAL
Intervention: Rapid MRI
Number of subjects: 380

Group type: COMPARATOR
Intervention: Radiograph
Number of subjects: 380